1 Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation
2 Delivering the Diagnosis Delivering the Diagnosis Day 1
3 Taking control of the situation After the initial shock wears off it is time to get to work Educate yourself on the disease and find out about your treatment options. This is a rare disease and a specialist is required There are many treatment options despite the rarity of your diagnosis
4 Hot New Drugs There are a number of new trials at some of our mesothelioma focused centers getting ready to or have recently opened. The next few slides will discuss these new drugs so you can become familiar with them
5 IGF-1 Insulin-Like Growth Factor 1 Secreted by the liver and thought to promote cell proliferation and apoptosis. A small number of publications have reported that targeting IGF-1 1 has demonstrated activity in mesothelioma cell lines
6 Vaccines WT-1 1 analog peptide vaccine WT-1 1 is a protein that is strongly expressed in 80% of mesothelioma tumors Clinical Trial will soon be available as an adjunct to surgery in pleural mesothelioma
7 HGF/SF and c-metc Interactions between c-met c receptor kinase and it ligand hepatocyte growth factor/scatter factor trigger signals responsible for cellular proliferation, survival, and migration There are a number of drugs in development and early phase clinical studies.
8 TGF Beta Transforming Growth Factor beta is a protein that plays a role in cell proliferation, and cell differentiation. Malignant cells lose the properties of normal cells and this process is referred to as cell differentiation.
9 TGR beta Cancerous cells increase production of TGF beta which impact on other cells Drugs have been developed that bind to TGF beta GC 1008 a drug in this class is now available in a clinical trial to mesothelioma patients that have failed prior therapies.
10 Cooperative Group Trials Sponsored by the National Cancer Institute Involves more than 3,100 institutions 14,000 individual investigators are registered and able to participate in this program 25,000+ participate in these cancer clinical trials per year
11 Cooperative Groups Cooperative groups include researchers, cancer centers, and community physicians throughout the United States, Canada, and Europe Researchers help to identify areas that need to be investigated and design trials that will generate data to answer specific questions
12 Cooperative Groups Thought leaders in the field of oncology participate in these groups. Working committee within these groups focus on specific disease In mesothelioma we are represented by many of the researchers that you have come to know and respect through the foundation
13 Eastern Cooperative Group ECOG Phase II Study of Anti-HGF Monoclonal Antibody AMG 102 in Combination With Pemetrexed Disodium and Cisplatin in Patients With Malignant Pleural Mesothelioma
14 AMG 102 in combination with Pemetrexed and Cisplatin AMG 102 is a fully human monoclonal antibody that blocks the action of hepatocyte growth factor/scatter factor The met receptor and it s ligand heptocyte growth factor regulate cell growth, survival and migration, and dysregulation of the HGF-MET pathway leads to oncogenic changes including tumor proliferation, angiogenesis and metastasis.
15 AMG 102 cont d Front line therapy for chemotherapy naïve patients, all histologies can participate in this trial
16 CALGB Study Phase II Randomized Study of Pemetrexed Disodium Maintenance Therapy Versus Observation in Patients With Malignant Pleural Mesothelioma Without Progression After First- Line Chemotherapy
17 CALGB cont d This is a trial for systemic chemotherapy naïve patients to determine if maintenance alimta will help to prevent recurrence of disease Randomized Phase II study Alimta cisplatin observation vs alimta cisplatin and maintenance with alimta following 6 cycles of tx
18 MORAb- OO9 A monoclonal antibody that targets mesothelin found on the outside of epithelial mesothelioma cells It is given in combination with pemetrexed (alimta( alimta) ) and cisplatin First line therapy for chemo naïve patients.
19 MORAb-009 cont d Preclinical data suggests that MORAB 009 works by blocking mesothelin's ability to interact with its target and second, by stimulating the patient's immune system to attack the tumor by specifically destroying those cells bound by MORAb-009.
20 MORAb-009 cont d Dr Raffit Hassan designed a Phase I trial and based upon his reported results this new trial was developed in conjunction with Morphotech Taking place in multiple site including Canada and Europe
21 CBP 501 Given in combination with pemetrexed and cisplatin G2 checkpoint inhibiting leads to sensitizing cancer cells to DNA- damaging anticancer agent without increasing adverse effects on normal cells
22 CBP 501 cont d Checkpoints occur during the G phase which when functioning stop the cell from producing daughter cell CBP 501 is thought to enhance this checkpoint and halt cancerous cells from replicating. It may also be synergistic with chemotherapy
23 CBP-501 This is a multi center trial taking place in the United States. It is a first line therapy for chemo naïve patients
24 Front line Treatment Some additional options that are offered at single centers include intracavitary administration of chemotherapy in conjunction with surgery Lung sparing therapy where intraplural chemotherapy and radiation therapy are administered without removal of lung or pleura
25 Front line therapy cont d IMRT delivered following 4 cycles of chemotherapy for patients in whom surgery is not an option. Chemotherapy or Targeted agents given prior to surgery or post surgery Gene therapy given in conjunction with chemotherapy either as first line or after treatment failure Immunotoxin in combination with chemotherapy
26 2nd Line Therapy SAHA Trial continues Multi center multi nation trial to determine if zolinza is better than placebo in the second line setting Currently there is no second line drug approved in mesothelioma
27 AZD 2171 Oral VEGF inhibitor 1 prior cytotoxic chemotherapy permitted Eligibility includes peritoneal, tunica vaginalis or pleural mesothelioma Multi Center Trial in the US and Canada
28 Salvage Therapy Strict definition is chemotherapy given after other treatments are found to be ineffective There are a number of centers that have Phase I or Phase II trials that permit multiple prior therapies. The Foundation remains your best source for learning about clinical trial options
29 Completed Trials A Phase I trial of SS1P was conducted in solid tumors which express mesothelin.. 14 patients with malignant both pleural and peritoneal mesothelioma participated in this study Due to the results of this phase 1 study a Phase I/II trial using SS1p plus pemetrexed and cisplatin is now accepting patients
30 Completed Trials cont d Dr Anna Nowak AU reported on a trial to evaluate the contribution of FDG/PET analysis to other prognostic variables. Results 89 eligible patients (28 underwent prior pleurodesis). Sarcomatoid histology found to be the strongest prognostic factor
31 Completed Trials cont d In this study FDG/PET parameters were more predictive of survival than TNM staging Possible that clinical decisions might be made on glycolytic activity, and tumor volume rather than traditional stage of disease emphasis.
32 Completed Trials cont d EPP F/by Intraoperative Hyperthermic Cisplain Purpose: study feasibility and safety of hyperthermic intraoperative intracavitary cisplatin perfusion following an EPP 121 enrolled patients with a median survival of 12.8 months
33 Completed Trials cont d Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma First retrospective study to demonstrate that cisplatin and pemetrexed improved lung function and exercise capactiy
34 Completed Trials cont d Multicenter trial of neo adjuvant pemetrexed and cisplatin prior to EPP Patients completing all therapy had a median survival of 29.1 months and a 2-2 year survival rate of 61.2%. Radiologic response of complete or partial response was associated with a median survival of 26.0 months compared with 13.9 months for patients with stable disease or progressive disease (P =.05).
35 Completed Trials cont d Report from an expanded access program for pemetrexed single agent or in combination with a platinum Response rates (95% CI) for PEM, PEM/CIS, and PEM/CARBO were 12.5% (3.5, 29.0), 20.0% (7.7, 38.6), and 24.1% (10.3, 43.5), respectively. Median survival for PEM was 10.3 months. One-year survival rates for PEM/CIS and PEM were 57.4% (95% CI: 10.3, 100) and 41.5% (95% CI: 4.6, 78.4), respectively, and were not available for PEM/CARBO.
36 Gene Therapy Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in a number of clinical trials over the last two decades. The next slide demonstrates a response in a pleural mesothelioma patient on a gene therapy trial
37 Gene Therapy Trials There are a number of new trial in development that will include chemotherapy combined with gene therapy. Trials will be for chemo naïve patients as well as those that have failed prior therapies.
39 Clinical Trial Participant There is hope We are making progress!
40 Inhibition of Il-1 1 as a Novel Target in Peritoneal Mesothelioma H. Richard Alexander, Jr., M.D. Associate Chair for Clinical Research Department of Surgery University of Maryland Medical Center
41 Inhibition of Il-1 1 as a Novel Target in Peritoneal Mesothelioma A study to characterize the molecular personality of MPM; the preliminary data show that a specific family of proteins are present in high levels with MPM tumors cells. MPM appears to require these proteins for continued growth and spread
42 Il-1 1 cont d Coincidently, there are inhibitors to these proteins that are being developed by pharmaceutical companies for other reasons The research proposal that MARF is supporting hypothesizes that inhibition of these proteins will be a possible effective and new strategy to treat patients with MPM
43 Il-1 1 cont d Preliminary data in the laboratory has supported the hypothesis; cells in which the protein is inhibited do not grow and die at a faster rate than untreted cells; the next step is to test the compound in laboratory mice with MPM tumors.
44 Enhanced Diagnostic Imaging and High Precision Gene Therapy of Mesothelioma Using Nontoxic Nanocarriers Gang Logan Liu, PhD Assistant Professor Mircro and Nanotechnology Lab University of Illinois
45 Enhanced Diagnostic Imaging and High Precision Gene Therapy of Mesothelioma Using Nontoxic Nanocarriers Developed better and non-toxic delivery nanocarriers for gene/chemo therapeutic drug to potentially improve the Mesothelioma therapy efficiency and mitigate systemic side effects
46 Nanocarriers cont d The gene/chemo therapeutic drug delivery by this nanocarrier is highly specific and localized to targeted cancer cells
47 Nanocarriers cont d The nanocarriers can serve as contrast agents in Mesothelioma diagnostic imaging besides of therapeutic benefits The gene/chemo therapeutic drug delivery by this nanocarrier is highly specific and localized to targeted cancer cells
48 Nanocarriers cont d The nanocarriers are made of FDA-approved materials and are either biodegradable or quickly metabolized With preliminary results stemming from this foundation funded grant, we have successfully received federal research grants to support our future work in testing the nanocarriers and targeted drug delivery in animal models
49 Combinatorial Targeting of Tyrosine Kinases that are Aberrantly Activated in Malignant Mesothelioma Haning Yang PhD Assistant Professor (Researcher), Cancer Research Center of Hawai i; i; Assistant Clinical Professor, Department of Pathology
50 Studies of Tumor Necrosis Factor alpha as a New Target for Human Malignant Mesothelioma Prevention We found that TNF-α and NF-kB pathway play critical roles in asbestos- induced oncogenesis and mesothelioma development We have established the in vitro (cell culture) and in vivo (animal-mouse) mouse) models for mesothelioma
51 Necrosis Factor cont d By using these models, we are testing whether by targeting TNF-α and/or NF-kB, we will be able to prevent mesothelioma development or whether we can inhibit tumor growth and invasion
52 The Hedgehog Signaling Pathway As A Target For Inhibiting Malignant Mesothelioma Growth Dr Steven Mutsaers Lung Institute of Western Australia (Inc) The University of Western Australia
53 Hedgehog Pathway cont d Increasing evidence supports an association between inappropriate activation of key proteins within a cell signalling pathway important for human development called the Hedgehog (HH) pathway
54 Hedgehog Pathway cont d Data from this labratory supports a role for the HH pathway in MM. Further studies using human cells and animal models are required to identify the best way to inhibit this pathway and prevent tumour growth
55 Combinatorial Targeting of Tyrosine Kinases that are Aberrantly Activated in Malignant Mesothelioma Joseph Testa PhD Carol & Kenneth E. Weg Chair in Human Genetics Co-Director, Cancer Biology Program Fox Chase Cancer Center
56 Combinatorial Targeting of Tyrosine Kinases that are Aberrantly Activated in Malignant Mesothelioma tested the idea of combinatorial targeted drug therapies in preclinical models of mesothelioma in hopes of demonstrating efficacy toward the clinical treatment of mesothelioma.
57 Conclusion The Foundation s s Grant Program is a leader in stimulating research into early detection, defining mechanisms contributing to malignancy and driving force behind new treatments being offered to mesothelioma patients.
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
An update in Mesothelioma and Thymoma Management ASCO 2014 update Khalid Alsaleh King Saud University FRCPC, FACP, MSc Mesothelioma Outline Outline Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health
MALIGNANT PLEURAL FLUIDS AID MESOTHELIOMA CELL GROWTH AND PROPAGATION HUI MIN CHEAH PhD Candidate School of Medicine and Pharmacology University of Western Australia Lung Institute of Western Australia
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
Mesothelioma Michele Carbone, M.D.,PH.D. Director Cancer Research Center of Hawaii Professor and Chairman, Dept. of Pathology J.A. Burns Medical School University of Hawaii Honolulu, HI 96813 Mesotheliomas
Introduction to the Mesothelioma Applied Research Foundation Who We Are Mission Statement The Meso Foundation is the only national non-profit dedicated to eradicating mesothelioma as a life-ending disease.
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
Overview of Mesothelioma Raffit Hassan, M.D. Mesothelioma Is an aggressive tumor that arises from the serosal surfaces of body cavities In 1960, Wagner reported increased incidence of mesothelioma in asbestos
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich
The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.
A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹Pernambuco
Better Care. Faster A new predictive algorithm for aiding clinical decision-making in lung cancer Y Kogan, I Sela, Y Kheiffetz, M Kleiman, Z Agur, Optimata Ltd., O Liran, N Peled, Sheba hospital, I Lazarev,
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis . Most are
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
Brochure More information from http://www.researchandmarkets.com/reports/2234830/ Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite
Lung Cancer International Volume 2015, Article ID 590148, 7 pages http://dx.doi.org/10.1155/2015/590148 Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
An Introduction To Immunotherapy And The Promise Of Tissue Phenomics INSIDE: n The Potential of Immunotherapy n Towards an Understanding of Immunotherapy n Current Approaches to Immunotherapy n The Immunotherapy
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article  December 01, 2003 By George W. Sledge, Jr, MD  Gemcitabine (Gemzar) and paclitaxel show good activity as single
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Malignant Mesothelioma Recent Advances Dr AS Paul 04 Aug 06 DM Seminar Malignant mesothelioma A tumour of serosal surfaces Pleura, peritoneum Increasing incidence worldwide Association with asbestos exposure
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill firstname.lastname@example.org Primary endpoints in Phase II trials Recently looked at journal articles
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Mazin Al-kasspooles, MD Associate Professor of Surgery Division of Surgical Oncology Director, Regional Therapy
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T